CHEMICALSEXPORTSCAPEXCDMOAGROCHEMICALSCHINA+1

India Specialty Chemicals: The ₹18,000 Cr Capex Cycle Is Finally Paying Off — But Three Cracks Are Widening

8 Jun 2026·9 min read·Free Report

30-second version

1.Navin Fluorine's CDMO revenue crossed ₹800 Cr in FY26 (up ~38% YoY), SRF's fluorochemicals segment EBIT margin recovered to 19.2% in Q4 FY26 after four consecutive quarters of compression — the earnings trough for the high-quality names appears to be behind us, not ahead.
2.DIIs added aggressively to PI Industries and SRF through Q1 CY26 even as FIIs trimmed; the institutional divergence signals domestic conviction on a multi-year China+1 structural play rather than a short-cycle tariff trade, with mutual fund AUM in chemicals-heavy mid/smallcap funds up ~₹4,200 Cr QoQ.
3.At 28-32x trailing PE, PI Industries and Navin Fluorine trade at a ~15% discount to their 5-year average multiples of 38-42x — not screaming cheap, but the first time since FY21 that you are buying these names below long-run valuation while earnings growth is re-accelerating rather than decelerating.

01What's happening

The India-US tariff framework announced in May 2026 effectively zeroed out the 10-25% reciprocal tariff on Indian specialty chemical exports to the US, which had been the single biggest overhang on agrochemical and CDMO order book visibility since April 2025. PI Industries immediately flagged on its Q4 FY26 call that two large US-based innovator clients who had paused multi-year CDMO contracts are now back at the negotiating table. Aarti Industries completed commissioning of its nitrotoluene derivatives complex at Dahej in March 2026 — ₹1,400 Cr capex, 18 months delayed from original schedule — and management guided for utilisation hitting 60-65% by Q2 FY27, which is the threshold needed to meaningfully lift consolidated EBITDA margins from the current 14.8% back toward the 18-20% band. SRF's refrigerant business got an unexpected boost: with the EU's F-gas regulation phase-down tightening HFC quotas from January 2026, Indian HFO and HFC producers are seeing spot inquiries jump 35-40% from European distributors, and SRF's Bhiwadi fluorochemicals plant is running at 91% utilisation as of May 2026. On the agrochemical side, Rallis India and UPL's domestic India business both reported channel inventory normalisation finally completing in Q4 FY26 after seven consecutive quarters of distributor destocking — primary sales grew 11% YoY in Q4 FY26 for Rallis vs the 3-4% of the prior six quarters. Japanese chemical majors Tosoh and Daicel are in active MOU discussions with Gujarat Industrial Development Corporation for greenfield investments, a direct consequence of Japan's 'China+1' policy formalised in early 2026, and this is creating real subcontracting pipeline for Navin Fluorine and Alkyl Amines.

02Why this matters for your portfolio

The specialty chemicals sector's investment case rests on three compounding drivers that are all moving simultaneously for the first time since FY22: export tariff clarity from the US deal, accelerating China+1 order flow from Japan and Europe, and domestic agrochemical demand recovering after the worst destocking cycle in a decade. The earnings math is straightforward — for PI Industries, every 10 percentage point increase in CSM (contract synthesis and manufacturing) revenue utilisation adds roughly ₹180-200 Cr to EBITDA at current mix; the company has ₹8,500 Cr of unexpired order book with delivery timelines of 3-5 years, and approximately 40% of that was effectively dormant through FY25-FY26 due to client inventory caution. Navin Fluorine's MPP (multi-purpose plant) at Dahanu, built at ₹1,100 Cr, is the single most important asset in the Indian CDMO fluorine space — there is no comparable capacity in the country, and the moat only grows as regulatory compliance costs make greenfield entry harder. ROCE across the listed specialty chemicals universe compressed from a peak of 21.4% in FY22 to 13.8% in FY25 — the entire de-rating from 50x to 28-32x PE is essentially this ROCE compression story, and the re-rating catalyst is the reverse journey back to 17-19% ROCE as new capacities fill up through FY27-FY28. The India-EU FTA, if finalised as signalled in Q1 CY26, adds a third export corridor on top of US and Japan for advanced intermediates and agrochem APIs — the EU is currently a ₹6,200 Cr annual market for Indian specialty chemicals and an FTA could realistically expand that 25-30% over three years. For a portfolio investor, this is one of the few domestic sectors where the structural narrative (de-risking of global supply chains away from China) is backed by actual order flows and capacity investments, not just conference-circuit optimism.

03Valuation check

Current multiples vs. 5-year averages. Verdict based on trailing twelve months earnings.

043 stocks worth watching

Fundamentally sound names with a clear thesis. Not buy/sell recommendations.

05Contrarian take

The bear case — what the bulls are missing

Here's what the bulls are missing: the capex cycle in Indian specialty chemicals has been so aggressive that aggregate sector debt has risen from ₹9,800 Cr in FY22 to an estimated ₹22,400 Cr in FY26 across the 15 largest listed players, and the assumption baked into every bull model is that utilisation ramps linearly to 70-80% within 6-8 quarters of commissioning. That has not happened once in the past decade for a major capacity addition in this sector — Aarti's nitrotoluene complex, Deepak Nitrite's phenol plant, and SRF's specialty chemicals expansion all took 12-18 months longer than guided to hit target utilisation, which means interest costs are running ahead of EBITDA contribution and working capital cycles are stretching. More specifically, PI Industries' customer concentration is a live risk that the market has stopped pricing: the top three innovator clients account for an estimated 58-62% of CSM revenue, and any one of them deciding to in-source or switch to a Chinese supplier post-tariff normalisation between China and the US — a scenario that is genuinely possible if US-China trade relations improve through late 2026 — would crater PI's earnings growth story. Agrochemical raw material costs (key intermediates like mancozeb, chlorpyrifos precursors) are still 15-18% above pre-2022 levels despite the destocking narrative, and if kharif sowing acreage disappoints on a below-normal monsoon — June 2026 IMD forecasts are already showing a 95% of LPA number which sounds fine but the spatial distribution is uneven — the domestic recovery trade falls apart quickly. Finally, Navin Fluorine at 38x trailing PE prices in flawless execution on MPP ramp; the MPP has already delivered two consecutive quarters of below-guidance revenue, and a third miss would compress the multiple back to 28-30x, implying 20-25% downside from current levels with no margin of safety.

06Sources

Primary sources only · No broker reports

Enjoyed this report?

Get a new one every Monday.

One flat plan — ₹199/month. Includes full archive, valuation tables, and watchlists.

Subscribe — ₹199/mo →